Daunorubicin-Cytarabine liposomal | Search results | NICE

Showing 1 to 2 of 2 results for daunorubicin-cytarabine liposomal

Sort by

Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)
Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia in adults.
Result type
Technology appraisal guidance
Published
19 December 2018
View recommendations for TA552
Show all sections
Sections for TA552
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Awaiting development Reference number: GID-TA10916 Expected publication date: TBC
Result type
Technology appraisal guidance
Status
Awaiting development